Hyperbilirubinemia Is Not a Major Contributing Factor to Altered Bone Mineral Density in Patients With Chronic Liver Disease

Journal of Clinical Densitometry

Volumn 9, Issue 1, 2006, Pages 105-113

  Smith, Darcey L H ^a   Shire, Norah J ^a   Watts, Nelson B ^a   Schmitter, Terri ^a   Szabo, Greta ^a   Zucker, Stephen D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Bilirubin; Gunn rat; hepatic osteodystrophy; liver disease; osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; OSTEOCALCIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE DENSITY; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HUMAN; HYPERBILIRUBINEMIA; LIVER GRAFT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OSTEODYSTROPHY; PRIORITY JOURNAL; RAT;

ADULT; AGED; ANIMALS; BILIRUBIN; BONE DENSITY; CHRONIC DISEASE; COMORBIDITY; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LIVER DISEASES; MALE; MIDDLE AGED; OSTEOCALCIN; RATS; RATS, GUNN;

EID: 33646843750     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2005.10.001     Document Type: Article

References (71)

1. Hay J.E. Bone disease in cholestatic liver disease. Gastroenterology 108 (1995) 276-283
2. Leslie W.D., Bernstein C.D., and Leboff M.S. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125 (2003) 941-966
3. Diamond T., Stiel D., Lunzer M., Wilkinson M., Roche J., and Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 31 (1990) 82-87
4. Van Berkum F.N., Beukers R., Birkenhager J.C., Kooij P.P., Schalm S.W., and Pols H.A. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology 99 (1990) 1134-1139
5. Hay J.E., Lindor K.D., Wiesner R.H., Dickson E.R., Krom R.A., and LaRusso N.F. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14 (1991) 257-261
6. Eastell R., Dickson E.R., Hodgson S.F., et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14 (1991) 296-300
7. Gallego-Rojo F.J., Gonzalez-Calvin J.L., Munox-Torres M., Mundi J.L., Fernandez-Perez R., and Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28 (1998) 695-699
8. Gonzalez-Calvin J.L., Gallego-Rojo F., Fernandez-Perez R., Casado-Caballero F., Ruiz-Escolano E., and Olivares E.G. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 89 (2004) 4325-4330
9. Guanabens N., Pares A., Marinoso L., et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 85 (1990) 1356-1362
10. Bagur A., Mautalen C., Findor J., Sorda J., and Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 63 (1998) 385-390
11. Baran D.T., Teitelbaum S.L., and Bergfeld M.A. Effects of alcohol ingestion on bone and mineral metabolism in rats. Am J Physiol 238 (1980) 507-510
12. Floreani A., Chiaramonte M., Giannini S., et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 12 (1991) 217-223
13. James C.H., Dickson E.R., Okazaki R., Bonde S., McDonagh A.F., and Riggs B.L. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95 (1995) 2581-2586
14. Vassilopoulou-Sellin R., Rey-Bear N., and Oyedeji C.O. Bilirubin as an inhibitor of cartilage metabolism: effect on avian chondrocyte proliferation in cell culture. J Bone Miner Res 5 (1990) 769-774
15. Vassilopoulou-Sellin R., and Oyedeji C.O. Tetrapyrroles as inhibitors of normal cartilage metabolism: relative potency of different compounds. J Bone Miner Res 3 (1988) 681-688
16. Vassilopoulou-Sellin R., Oyedeji C.O., and Samaan N.A. Bilirubin inhibits cartilage metabolism and growth in vitro. Metabolism 38 (1989) 759-762
17. Vassilopoulou-Sellin R., Foster P., and Oyedeji C.O. Bilirubin and heme as growth inhibitors of chicken embryos in ovo. Pediatr Res 27 (1990) 617-621
18. Newton J., Francis R., Prince M., James O., Bassendine M., Rawlings D., and Jones D. Osteoporosis in primary biliary cirrhosis revisited. Gut 49 (2001) 282-287
19. Menon K.V.N., Angulo P., Weston S., Dickson E.R., and Lindor K.D. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35 (2001) 316-323
20. Ormarsdóttir S., Ljunggren O., Mallmin H., Michaëlsson K., and Lööf L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 14 (2002) 43-48
21. Lindor K.D., Janes C.H., Crippin J.S., Jorgensen R.A., and Dickson E.R. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. Hepatology 21 (1995) 389-392
22. Conn H.O. A peek at the Child-Turcotte classification. Hepatology 1 (1981) 673-676
23. Malinchoc M., Kamath P.S., Gordon F.D., Peine C.J., Rank J., and ter Borg P.C.J. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 (2000) 864-871
24. Pares A., and Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis 7 (2003) 779-794
25. Roll J., Boyer J.L., Barry D., and Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 308 (1983) 1-7
26. Bonnand A.M., Heathcote E.J., Lindor K.D., and Poupon R.E. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29 (1999) 39-43
27. Iyanagi T., Watanabe T., and Uchiyama Y. The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a -1 frameshift mutation. J Biol Chem 264 (1989) 21302-21307
28. Stobie P.E., Hansen C.T., Hailey J.R., and Levine R.L. A difference in mortality between two strains of jaundiced rats. Pediatrics 87 (1991) 88-93
29. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 843 (1994) 1-129
30. Zucker S.D., Qin X., Rouster S.D., et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 98 (2001) 12671-12676
31. Hassoun A.A., Nippoldt T.D., Tiegs R.D., and Khosla S. Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 103 (1997) 70-73
32. Clarke B.L., Ebeling P.R., Jones J.D., Wahner H.W., O'Fallon W.M., Riggs B.L., and Fitzpatrick L.A. Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int 70 (2002) 137-145
33. Tromp A.M., Ooms M.E., Popp-Snijders C., Roos J.C., and Lips P. Predictors of fractures in elderly women. Osteoporos Int 11 (2000) 134-140
34. Iida H., and Fukuda S. Age-related changes in bone mineral density, cross-sectional area and strength at different skeletal sites in male rats. J Vet Med Sci 64 (2002) 29-34
35. Banu J., Wang L., and Kalu D.N. Age-related changes in bone mineral content and density in intact male F344 rats. Bone 30 (2002) 125-130
36. Nielsen S.P., Kolthoff N., Bärenholdt O., Kristensen B., Abrahamsen B., Hermann A.P., and Brot C. Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded. Br J Radiol 71 (1998) 934-943
37. Saland J.M., Goode M.L., Haas D.L., Romano T.A., and Seikaly M.G. The prevalence of osteopenia in pediatric renal allograft recipients varies with the method of analysis. Am J Transplant 1 (2001) 243-250
38. Wu X.P., Liao E.Y., Liu S.P., Zhang H., Shan P.F., Cao X.Z., and Jiang Y. Relationship of body surface area with bone density and its risk of osteoporosis at various skeletal regions in women of mainland China. Osteoporos Int 15 (2004) 751-757
39. Wang J., Thornton J.C., Horlick M., Formica C., Wang W., and Pierson R.N. Dual X-ray absorptiometry in pediatric studies: changing scan modes alters bone and body composition measurements. J Clin Densitom 2 (1999) 135-141
40. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 30 (1997) 573-593
41. van der Merwe S.W., van den Bogaerde J.B., Goosen C., et al. Hepatic osteodystrophy in rats results mainly from portosystemic shunting. Gut 52 (2003) 580-585
42. Rude R.K., Gruber H.E., Norton H.J., Wei L.Y., Frausto A., and Mills B.G. Bone loss induced by dietary magnesium reduction to 10% of the nutrient requirement in rats is associated with increased release of substance P and tumor necrosis factor-α. J Nutr 134 (2004) 79-85
43. Ravin P., Thompson D.E., Ross P.D., and Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33 (2003) 150-158
44. Akesson B., Ljunghall S., Gardsell P., Sernbo I., and Obrant K.J. Serum osteocalcin and fracture susceptibility in elderly women. Calcif Tissue Int 53 (1993) 86-90
45. McGuigan F.E.A., Ambrecht G., Smith R., Felsenberg D., Reid D.M., and Ralston S.H. Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12 (2001) 91-96
46. Guanabens N., Pares A., Alvarez L., et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 13 (1998) 731-738
47. Trautwein C., Possienke M., Schlitt H.J., et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 95 (2000) 2343-2351
48. Sokhi R.P., Anantharaju A., Kondaveeti R., Creech S.D., Islam K.K., and Van Thiel D.H. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transplant 10 (2004) 648-653
49. Ninkovic M., Love S.A., Tom B., Alexander G.J.M., and Compston J.E. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 69 (2001) 321-326
50. Giannini S., Nobile M., Dalle Carbonare L., et al. Vertebral morphometry by X-ray absorptiometry before and after liver transplant: a cross-sectional study. Eur J Gastroenterol Hepatol 13 (2001) 1201-1207
51. Shapiro J.M., Smith H., and Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20 (1979) 137-140
52. Rapin C.H., and Lagier R. Raised serum albumin in hip osteoarthrosis: a comparative study in women of some blood chemical parameters in aging and in cases of femoral neck fractures, osteoporotic vertebral crush fractures, and hip osteoarthrosis. Ann Rheum Dis 47 (1988) 576-581
53. Li Y.Q., Prentice D.A., Howard M.L., Mashford M.L., and Desmond P.V. Bilirubin and bile acids may modulate their own metabolism via regulating uridine diphosphate-glucuronosyltransferase expression in the rat. J Gastroenterol Hepatol 15 (2000) 865-870
54. Munoz M.E., Esteller A., and Gonzalez J. Substrate induction of bilirubin conjugation and biliary excretion in the rat. Clin Sci 73 (1987) 371-375
55. Huang W., Zhang J., Chua S.S., Qatanani M., Han Y., Granata R., and Moore D.D. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 100 (2003) 4156-4161
56. Scharschmidt B.F., Blanckaert N., Farina F.A., Kabra P.M., Stafford B.E., and Weisiger R.A. Measurement of serum bilirubin and its mono- and diconjugates: application to patients with hepatobiliary disease. Gut 23 (1982) 643-649
57. Blanckaert N., Kabra P.M., Farina F.A., Stafford B.E., Marton L.J., and Schmid R. Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography. J Lab Clin Med 96 (1980) 198-212
58. Jansen P.L.M., Groothuis G.M.M., Peters W.H.M., and Meijer D.K.F. Selective hepatobiliary transport defect for organic anions and neutral steroids in mutant rats with hereditary conjugated hyperbilirubinemia. Hepatology 7 (1987) 71-76
59. Paulusma C.C., and Oude Elferink R.P.J. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 75 (1997) 420-428
60. Bosma P.J., Chowdhury N.R., Goldhoorn B.G., Hofker M.H., Oude Elferink R.P., Jansen P.L., and Chowdhury J.R. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 15 (1992) 941-947
61. Kadakol A., Ghosh S.S., Sappal B.S., Sharma G., Roy Chowdhury J., and Roy Chowdhury N. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 16 (2000) 297-306
62. Lee A.J., Hodges S., and Eastell R. Measurement of osteocalcin. Ann Clin Biochem 37 (2000) 432-446
63. Delmas P.D., Hardy P., Garnero P., and Dain M.P. Monitoring individual response to hormone replacement therapy with bone markers. Bone 26 (2000) 553-560
64. Diamond T.H., Stiel D., Lunzer M., McDowall D., Eckstein R.P., and Posen S. Hepatic osteodystrophy: static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96 (1989) 213-221
65. Monegal A., Navasa M., Guanabens N., et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60 (1997) 148-154
66. Klein G.L., Soriano H., Shulman R.J., Levy M., Jones G., and Langman C.B. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 6 (2002) 136-140
67. Capra F., Casaril M., Gabrielli G.B., et al. Plasma osteocalcin levels in liver cirrhosis. Ital J Gastroentrol 23 (1991) 124-127
68. Hamdy R.D., Petak S.M., and Lenchik L. Which central dual X-ray absorptiometry skeletal sites and regions of interest should be used to determine the diagnosis of osteoporosis?. J Clin Densitom 5 (2002) S11-S17
69. Ostrow J.D., Pascolo L., and Tiribelli C. Reassessment of the unbound concentrations of unconjugated bilirubin in relation to neurotoxicity in vitro. Pediatr Res 54 (2003) 98-104
70. Zhang X., Schwarz E.M., Young D.A., Puzas J.E., Rosier R.N., and O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109 (2002) 1405-1415
71. Wang W.W., Smith D.L.H., and Zucker S.D. Bilirubin inhibits iNOS expression and nitric oxide production in response to endotoxin. Hepatology 40 (2004) 424-433